Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. Following the closing of the merger, Catalyst's common stock has ceased trading on the Nasdaq Global Market and the company has been integrated into Angelini Pharma as a wholly owned subsidiary. The transaction was supported by €1 billion investments from both Blackstone and CDP Equity, with CDP Equity acquiring a 23.5% stake in Angelini Pharma's common equity to support the global expansion.
CPRX: 25-NSE · delisting
Catalyst Pharmaceuticals, Inc. has filed a Form 25-NSE with the SEC, formally notifying the removal of its securities from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. This submission indicates that the company's stock will no longer be traded on a national exchange, a development that severely impacts liquidity and shareholder value. Investors should anticipate a transition to over-the-counter trading or a complete suspension of trading activity.
Solaris Energy Infrastructure Set to Join S&P SmallCap 600
S&P Dow Jones Indices announced that Catalyst Pharmaceuticals will be removed from the S&P SmallCap 600 effective July 15, 2026. The deletion is due to the company's pending acquisition by Angelini Pharma S.p.A., which is expected to close soon pending final conditions. Solaris Energy Infrastructure Inc. is set to replace Catalyst Pharmaceuticals in the index prior to the market open.
CPRX: 8-K · acquisition merger
Catalyst Pharmaceuticals stockholders approved the company's merger with Angelini Pharma S.p.A., paving the way for the transaction to close. The proposal received 97.3 million votes in favor, significantly surpassing the votes against and abstentions. All current directors of the Company, including Patrick J. McEnany and Richard J. Daly, intend to resign from the board effective immediately upon the closing of the merger. The board resignations are not due to any disagreement with the company's operations or policies. While shareholders approved the merger itself, they voted against the non-binding advisory proposal regarding executive compensation related to the deal. The compensation proposal failed with approximately 67.4 million votes against and 30.5 million votes in favor.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
Catalyst Pharmaceuticals reported topline results from a Phase 1 study showing vamorolone exhibits anti-inflammatory activity without significant immunosuppression at clinical doses. Part A data from 24 adults demonstrated similar cortisol suppression to deflazacort at label-based doses, confirming current DMD dosing is appropriate without adjustments needed when switching therapies. Part B findings in 36 volunteers indicated clinically relevant immunosuppression only at supratherapeutic doses (40 mg/kg), suggesting a favorable safety profile for potential use in other chronic inflammatory rare diseases.
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating the proposed sale of Catalyst Pharmaceuticals to Angelini Pharma S.p.A. for potential violations of federal securities laws or breaches of fiduciary duties. The transaction is valued at $31.50 per share in cash, and the firm is examining whether the deal terms adequately protect shareholder interests against superior competing offers. Shareholders are being encouraged to contact the law firm to discuss their rights and options regarding the investigation on a contingent fee basis.
Catalyst Pharmaceuticals announced that the Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period regarding its proposed merger with Angelini Pharma on June 16, 2026. The transaction, initially agreed upon on May 6, 2026, remains subject to the adoption of the Merger Agreement by holders of a majority of the outstanding shares of Catalyst's common stock and other customary closing conditions. The parties currently expect the merger to close in the third quarter of 2026, pending the satisfaction or waiver of these remaining conditions.
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
CPRX: DEFM14A · acquisition merger
Catalyst Pharmaceuticals, Inc. (CPRX) has entered into a definitive agreement to be acquired by Angelini Pharma S.p.A. for $31.50 per share in cash. The transaction represents a 21% premium to CPRX’s unaffected closing price on April 22, 2026, and a 28% premium to the 30-day volume-weighted average price. Stockholders will vote on the merger proposal at a special meeting scheduled for July 8, 2026. The Catalyst Board of Directors unanimously recommends approval, citing a fairness opinion from J.P. Morgan Securities LLC that the consideration is fair from a financial point of view. Upon closing, CPRX will be delisted from Nasdaq and become a wholly owned subsidiary of Angelini Pharma. Angelini has secured debt financing commitments totaling approximately $4.5 billion in aggregate principal amount to fund the transaction, including facilities from BNP Paribas.
CPRX: PREM14A · acquisition merger
Catalyst Pharmaceuticals, Inc. (CPRX) is soliciting stockholder approval for a definitive agreement to be acquired by Angelini Pharma S.p.A. in an all-cash transaction valued at $31.50 per share. The Board of Directors unanimously recommends the merger, citing a fairness opinion from J.P. Morgan that the consideration is fair from a financial point of view. The merger consideration represents a 21% premium to Catalyst’s unaffected closing share price on April 22, 2026, and a 28% premium to the 30-day volume-weighted average price. Upon completion, expected in the third quarter of 2026, Catalyst will become a wholly owned subsidiary of Angelini Pharma, and its shares will be delisted from Nasdaq. Angelini Pharma has secured financing commitments totaling approximately $3.5 billion in various facilities from BNP Paribas to fund the transaction. If the merger fails to close due to a lack of stockholder approval or other specified reasons, Catalyst may be required to pay a termination fee of $155.5 million to Angelini Pharma.
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the proposed sales of CPRX, UNF, RMAX, and ACR. The firm is concerned that insiders may receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation.
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
Catalyst Pharmaceuticals reported Q1 2026 total revenue of $149.3 million, up 5.6% year-over-year, driven by an 18.1% increase in FIRDAPSE revenue and a 66.6% surge in AGAMREE revenue. Profitability received a significant boost as the tiered royalty structure on FIRDAPSE expired in January 2026, reducing the overall royalty rate to 6% from a previous maximum of 18.5%. Despite the strong operational performance and a cash position of $755.9 million with no funded debt, the company suspended forward-looking guidance and canceled its earnings conference call, referencing a May 7 announcement.
CPRX: 10-Q · periodic report
Catalyst Pharmaceuticals, Inc. reported total revenues of $149.4 million for the three months ended March 31, 2026, a 5.6% increase from $141.4 million in the same period of 2025. The increase was primarily driven by higher sales volumes of FIRDAPSE® and AGAMREE®. The company's net income for the quarter was $63.7 million, or $0.52 per basic share, compared to $56.7 million, or $0.47 per basic share, in the same period of 2025. This represents an 11.6% increase in net income. Catalyst Pharmaceuticals, Inc. had a cash and cash equivalents position of $755.9 million as of March 31, 2026, up from $709.2 million at December 31, 2025. The company believes it has sufficient funds to support operations for at least the next 12 months. The company's total debt as of March 31, 2026, was $280,000, a minimal amount compared to its cash position.
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the proposed transactions of CPRX, TBRG, MDV, and ACR. The firm is concerned that insiders may receive substantial financial benefits not available to ordinary shareholders, and that the terms of the transactions may limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. The firm may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders.
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
Catalyst Pharmaceuticals has cancelled its first quarter 2026 earnings conference call and webcast due to a pending acquisition by Angelini Pharma S.p.A. The company still plans to release its Q1 2026 financial results after the market close on May 11, 2026. The cancellation follows the announcement of the acquisition, restricting the company's ability to provide standard operational guidance.
Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The purchase price reflects a 28% premium to the 30-day volume-weighted average trading price and a 21% premium to the unaffected closing price as of April 22, 2026. The transaction, which is not subject to a financing condition, is expected to close in the third quarter of 2026 and follows the resolution of Catalyst's pending FIRDAPSE patent litigation.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Catalyst Pharmaceuticals settled all remaining patent litigation regarding FIRDAPSE with Hetero Labs, resolving the final outstanding challenge to the drug's exclusivity. Under the agreement, Hetero is licensed to launch a generic version no earlier than January 2035, effectively extending protection for the company's flagship product. This settlement follows similar resolutions with Lupin, Teva, and Inventia, eliminating legal overhang and securing the revenue stream through the next decade.
Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards?
Catalyst Pharmaceutical (CPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Catalyst Pharmaceuticals scheduled the release of its first quarter 2026 financial results for after the market close on Monday, May 11, 2026. Management will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss the results and provide a business update.
Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable
Strength Seen in Catalyst (CPRX): Can Its 6.7% Jump Turn into More Strength?
Does Catalyst (CPRX) Have the Potential to Rally 28.87% as Wall Street Analysts Expect?
See How Institutions Boost Catalyst Shares
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
